The Byzantine Forum
Newest Members
son of the desert, chchannel, OrbisNonSufficit, SergLts, RusFrog
5656 Registered Users
Who's Online Now
0 registered members (), 157 guests, and 167 spiders.
Key: Admin, Global Mod, Mod
Latest Photos
Byzantine Nebraska
Church of the Holy Trinity (UGCC) - Brazil
Papal Audience 10 November 2017
Upgraded Russian icon corner
Russian Greek Catholic Global Congress
Forum Statistics
Forums26
Topics34,877
Posts412,856
Members5,656
Most Online3,380
Dec 29th, 2019
Previous Thread
Next Thread
Print Thread
Page 2 of 2 1 2
Re: Liturgy when there is no Liturgy [Re: Utroque] #420116 07/31/20 05:28 PM
Joined: Nov 2001
Posts: 6,540
Administrator Offline
John
Member
Offline
John
Member
Joined: Nov 2001
Posts: 6,540
The whole thing is strange. It's true that there have been no formal studies that hydroxychloroquine helps to cure the Coronavirus. But long use for malaria show that it's not harmful for people to take. Since there is some evidence that it helps, the appropriate thing to do is to let doctors prescribe it for their patients if they want.

As to the process to develop a vaccine, that needs to go through the regular process. It's certainly appropriate to speed up the paperwork part of things. Often, when a new drug is sent to the FDA for approval it goes to the end of the line where it sits in the queue. Speeding that up could cut a year off the approval process. But don't shortcut the science.

Re: Liturgy when there is no Liturgy [Re: Utroque] #420119 08/01/20 09:38 PM
Joined: Jul 2005
Posts: 2,628
Michael_Thoma Offline
Member
Offline
Member
Joined: Jul 2005
Posts: 2,628
The FDA's listed side effects for approved use, of course unapproved uses may increase these, especially for those with undiagnosed underlying conditions:

SIDE EFFECTS
The following adverse reactions have been identified during post-approval use of PLAQUENIL or other 4-aminoqunoline compounds. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders : Bone marrow failure, anemia, aplastic anemia, agranulocytosis, leukopenia, and thrombocytopenia. Hemolysis reported in individuals with glucose-6- phosphate dehydrogenase (G-6-PD) deficiency.

Cardiac disorders : Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome (see WARNINGS and OVERDOSAGE). PLAQUENIL prolongs the QT interval. Ventricular arrhythmias and torsade de pointes have been reported in patients taking PLAQUENIL (see OVERDOSAGE and DRUG INTERACTIONS).

Ear and labyrinth disorders : Vertigo, tinnitus, nystagmus, nerve deafness, deafness.

Eye disorders : Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance), visual field defects (paracentral scotomas) and visual disturbances (visual acuity), maculopathies (macular degeneration), decreased dark adaptation, color vision abnormalities, corneal changes (edema and opacities) including corneal deposition of drug with or without accompanying symptoms (halo around lights, photophobia, blurred vision).

Gastrointestinal disorders : Nausea, vomiting, diarrhea, and abdominal pain.

General disorders and administration site conditions : Fatigue.

Hepatobiliary disorders : Liver function tests abnormal, hepatic failure acute.

Immune system disorders : Urticaria, angioedema, bronchospasm

Metabolism and nutrition disorders : Decreased appetite, hypoglycemia, porphyria, weight decreased.

Musculoskeletal and connective tissue disorders : Sensorimotor disorder, skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups, depression of tendon reflexes and abnormal nerve conduction.

Nervous system disorders : Headache, dizziness, seizure, ataxia and extrapyramidal disorders such as dystonia, dyskinesia, and tremor have been reported with this class of drugs.

Psychiatric disorders : Affect/emotional lability, nervousness, irritability, nightmares, psychosis, suicidal behavior.

Skin and subcutaneous tissue disorders : Rash, pruritus, pigmentation disorders in skin and mucous membranes, hair color changes, alopecia. Dermatitis bullous eruptions including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), photosensitivity, dermatitis exfoliative, acute generalized exanthematous pustulosis (AGEP). AGEP has to be distinguished from psoriasis, although PLAQUENIL may precipitate attacks of psoriasis. It may be associated with pyrexia and hyperleukocytosis.
______________________________________________

Ocular
Irreversible retinal damage has been observed in some patients who had received hydroxychloroquine sulfate. Significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease.

A baseline ocular examination is recommended within the first year of starting PLAQUENIL. The baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT).

For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate greater than 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT. For individuals without significant risk factors, annual exams can usually be deferred until five years of treatment.

In individuals of Asian descent, retinal toxicity may first be noticed outside the macula. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees.

It is recommended that hydroxychloroquine be discontinued if ocular toxicity is suspected and the patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy.

Cardiac Effects, Including Cardiomyopathy And QT prolongation
Postmarketing cases of lifethreatening and fatal cardiomyopathy have been reported with use of PLAQUENIL as well as with use of chloroquine. Patients may present with atrioventricular block, pulmonary hypertension, sick sinus syndrome or with cardiac complications. ECG findings may include atrioventricular, right or left bundle branch block. Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment. Clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during PLAQUENIL therapy. Chronic toxicity should be considered when conduction disorders (bundle branch block/atrioventricular heart block) or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of PLAQUENIL may prevent life-threatening complications.

PLAQUENIL prolongs the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking PLAQUENIL (see OVERDOSAGE). Therefore, PLAQUENIL should not be administered with other drugs that have the potential to prolong the QT interval (see DRUG INTERACTIONS).

Worsening Of Psorias Is And Porphyria
Use of PLAQUENIL in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. The preparation should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the possible hazard.

Proximal Myopathy And Neuropathy
Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes. Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with PLAQUENIL.

Neuropsychiatric events, Including Suicidality
Suicidal behavior has been rarely reported in patients treated with PLAQUENIL.

Hypoglycemia
PLAQUENIL has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications (see DRUG INTERACTIONS and ADVERSE REACTIONS). Patients treated with PLAQUENIL should be warned about the risk of hypoglycemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with PLAQUENIL should have their blood glucose checked and treatment reviewed as necessary.
________________________________
PRECAUTIONS
General
Use with caution in patients with gastrointestinal, neurological, or blood disorders, and in those with a sensitivity to quinine.

Hepatic/Renal Disease
Antimalarial compounds should be used with caution in patients with hepatic disease or alcoholism, or in conjunction with known hepatotoxic drugs. A reduction in dosage may be necessary in patients with hepatic or renal disease, as well as in those taking medicines known to affect these organs.

Hematologic Effects /Laboratory Tests
Antimalarial compounds should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs. Periodic blood cell counts should be performed if patients are given prolonged therapy. If any severe blood disorder such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia, appears which is not attributable to the disease under treatment, consider discontinuation of PLAQUENIL.

PLAQUENIL should be administered with caution in patients having glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.

Dermatologic Effects
Dermatologic reactions to PLAQUENIL may occur and, therefore, proper care should be exercised when it is administered to any patient receiving a drug with a significant tendency to produce dermatitis.

Carcinogenesis, Mutagenesis, Impairment Of Fertility
Long-term studies in animals have not been conducted to evaluate the carcinogenic potential of PLAQUENIL.

The mutagenic potential of hydroxychloroquine was not evaluated. However, chloroquine has been shown to be a catalytic inhibitor of DNA repair enzymes (topoisomerase II) and to produce weak genotoxic effects through this mode of action.

Pregnancy
Teratogenic Effects
Human pregnancies resulting in live births have been reported in the literature and no increase in the rate of birth defects has been demonstrated. Embryonic deaths and malformations of anophthalmia and microphthalmia in the offspring have been reported when pregnant rats received large doses of chloroquine.

Nursing Mothers
Caution should be exercised when administering PLAQUENIL to nursing women. It has been demonstrated that hydroxychloroquine administered to nursing women is excreted in human milk and it is known that infants are extremely sensitive to the toxic effects of 4-aminoquinolines.

Pediatric Use
Safety and efficacy have not been established in the chronic use of PLAQUENIL for systemic lupus erythematosus and juvenile idiopathic arthritis in children. Children are especially sensitive to the 4-aminoquinoline compounds. Most reported fatalities followed the accidental ingestion of chloroquine, sometimes in small doses (0.75 g or 1 g in one 3-year-old child). Patients should be strongly warned to keep these drugs out of the reach of children (see OVERDOSAGE).

Geriatric Use
Clinical studies of PLAQUENIL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function.

Last edited by Michael_Thoma; 08/01/20 09:42 PM.
Page 2 of 2 1 2

Moderated by  Alice, Father Deacon Ed, theophan 

The Byzantine Forum provides message boards for discussions focusing on Eastern Christianity (though discussions of other topics are welcome). The views expressed herein are those of the participants and may or may not reflect the teachings of the Byzantine Catholic or any other Church. The Byzantine Forum and the www.byzcath.org site exist to help build up the Church but are unofficial, have no connection with any Church entity, and should not be looked to as a source for official information for any Church. All posts become property of byzcath.org. Contents copyright - 1996-2020 (Forum 1998-2020). All rights reserved.
Powered by UBB.threads™ PHP Forum Software 7.7.3